New England Journal of Medicine published a clinical update in Research Highlights on 01 Apr 2026. The item focuses on Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer. Review the original article for the full source wording and details.
New England Journal of Medicine, Volume 394, Issue 13 , Page 1352-1352, April 2, 2026.